R&D Team
Kong Wei
Founder and Vice Chairman of Baike Bio
Dr. [Name] graduated from Jilin University with a Ph.D. From 1995 to 1996, he conducted postdoctoral research at the School of Pharmacy of the University of Maryland in the United States; from 1996 to 2002, he pursued postdoctoral studies at the Johns Hopkins University School of Medicine and the Bloomberg School of Public Health. In 2004, he founded Bio-Thera Solutions and has since led the company’s R&D and management teams in the research and development of several biologic vaccines, including a lyophilized intranasal live attenuated influenza vaccine, an adsorbed acellular DTP vaccine, and cancer vaccines. Among these, the live attenuated varicella vaccine, the human rabies vaccine (Vero cell–derived), and the lyophilized intranasal live attenuated influenza vaccine have been approved for market launch and have delivered significant economic and social benefits.
Key Work Experience and Honors:
Since 2004, Director and General Manager of Changchun Bio-Pharmaceutical Technology Co., Ltd.;
Since 2002, Professor and Doctoral Supervisor at the College of Life Sciences, Jilin University;
In 2005, was awarded the “Special Government Allowance of the State Council”;
In 2005, the State Council Overseas Chinese Affairs Office awarded the inaugural “Outstanding Entrepreneurial Award for Overseas Chinese and Chinese Diaspora Professionals.”
In 2009, selected as a national-level candidate under the “New Century Hundred-Thousand-Ten Thousand Talents Program.”
In 2011, was awarded the honorary title of “Senior Expert of Jilin Province” in the third batch.
In 2012, recipient of the National May Day Labor Medal;
In 2012, selected as a Tier-1 candidate in the third batch of Jilin Province’s Top-notch Innovative Talents program;
In 2015, was awarded the honorary title of “Senior Expert of Jilin Province” in the fourth batch.
Jiang Chunlai
General Manager and Director of the Pharmaceutical Research Institute
Ph.D. in Biochemistry and Molecular Biology from the College of Life Sciences at Jilin University; postdoctoral research at the Duke University School of Medicine in the United States.
The organization has successfully completed the research and development and industrialization of the Baike Biotech intranasal live attenuated influenza vaccine, as well as the clinical trial application for the adsorbed acellular DTP (three-component) combination vaccine. Over the past five years, more than 50 SCI-indexed papers have been published, and seven authorized invention patents have been obtained. The organization has also served as the principal investigator for one sub-project under the National Key Science and Technology Major Project during the 12th Five-Year Plan period, one National Natural Science Foundation General Program project, one major science and technology tackling project, one key project, and one industrialization project funded by the Jilin Provincial Department of Science and Technology, as well as one special project for the construction of a demonstration site for industry–university–research collaborative innovation in Changchun City, and has received three provincial- or ministerial-level scientific research and academic awards.
Key Work Experience and Honors:
From July 1995 to June 2001, he served at the Changchun Institute of Biological Products, holding the positions of Technician and Assistant Engineer.
Since October 2001, he has been employed at the School of Life Sciences and the National Engineering Laboratory for AIDS Vaccine at Jilin University, holding successive positions as Lecturer, Associate Professor, Professor, and Doctoral Supervisor.
From July 2006 to July 2009, conducted postdoctoral research at the Duke University School of Medicine in the United States.
Since July 2009, has been employed by this company, holding successive positions as Director of R&D, Deputy General Manager, Executive Deputy General Manager concurrently serving as President of the Pharmaceutical Research Institute, and Director.
Since February 2018, has served as General Manager at Wellcome Biotech.
Since February 2018, has served as a director at Ruizhou Biotechnology.
Awarded the title of “First-Tier Candidate for Jilin Province’s Outstanding Innovative Talent”
Awarded the First Prize of the Jilin Provincial Science and Technology Award
Wei Wei
Deputy General Manager
Graduated from the College of Life Sciences at Jilin University with a Master’s degree in Bioengineering; Senior Engineer.
Led the development of mainstream vaccine manufacturing processes, enhancing both product yield and quality; integrated the end-to-end logistics system from procurement to finished-product warehousing, thereby significantly improving operational efficiency.
Since August 2004, he has been employed by the company, holding successive positions as Manager of the Production Management Department and Director of Production. He currently serves as Deputy General Manager, overseeing the production system and responsible for its overall operations.
Liu Dawei
Deputy General Manager
Ph.D. in Biochemistry and Molecular Biology from the College of Life Sciences, Jilin University; postdoctoral research at the Institute of Microbiology, Chinese Academy of Sciences.
Engaged in biopharmaceutical R&D, pilot-scale manufacturing, process technology transfer, and commercial-scale production management and quality assurance. Has participated in the research and development and commercialization of various viral vaccines, bacterial vaccines, and recombinant protein vaccines, as well as related studies on T-cell immunity and rabies virus monoclonal antibodies.
Since October 2014, he has successively held the positions of Project Manager, Technical Director, and Quality Director. He currently serves as Deputy General Manager and Head of Quality, overseeing the quality management system and responsible for its overall operation.
Shi Nianmin
Clinical Director, Deputy Director of the Institute of Pharmaceutical Research
Master’s degree in Epidemiology and Statistics from the School of Statistics at Renmin University of China.
With 30 years of experience in disease prevention, she has led numerous major public health emergency response and vaccine deployment initiatives. She has served as the principal investigator for clinical trials of several new vaccines, including those for influenza A (H1N1), EV71, 13-valent pneumococcal disease, HPV, varicella, rabies monoclonal antibodies, and rabies vaccine. She is a member of the editorial board and chief translator for the fifth and sixth editions of VACCINE, and associate editor of the Vaccine Use Manual. She has authored or co-authored nearly 50 peer-reviewed papers published in SCI-indexed journals, as well as contributed to the writing and compilation of numerous books and monographs.
Key Work Experience and Honors:
Chief Physician, Standing Committee Member and Secretary-General of the Clinical Vaccine Committee of the Chinese Society of Preventive Medicine
Vice Chairman and Secretary-General of the Vaccine Clinical Subcommittee of the China Vaccine Industry Association
Executive Vice President and Secretary-General of the Beijing Society for Biological Products
Part-time professor and master’s supervisor at Shanxi Medical University, Xiamen University, Hebei Medical University, Baotou Medical College, and other institutions.
Previously served as an reviewer at the National Medical Products Administration’s Center for Drug Evaluation and an inspector at the Center for Inspection and Verification.
Member of the Editorial Board of the Journal of Chronic Diseases
Member of the Editorial Board of “China Rational Drug Use”
Member of the Editorial Committee of “Inquiring About Medicine and Drugs”
From 2006 to 2017, served as Director of the Emergency Office of the Chaoyang District Center for Disease Control and Prevention in Beijing, Head of Biological Products Management, and Director of the Vaccine Clinical Evaluation Center.
Since October 2017, has served as the Company’s Clinical Director and Deputy Dean of the Drug Research Institute.
Two provincial- or ministerial-level awards have been received for research achievements.
National Outstanding Health Inspector
Top Ten Young People of Baotou City, etc.
Zhu Changlin
Secretary of the Party Branch, Chairman of the Trade Union, and Chief Engineer of Baike Biotechnology.
Graduated from the former Bethune Medical University with a Bachelor’s degree in Clinical Medicine (now the Bethune School of Medicine at Jilin University). A member of the Communist Party of China. Currently employed at Changchun Bio-Pharmaceutical Co., Ltd., where he holds the title of Senior Engineer. He has led the research and development of, and obtained approval for, “New Drug Certificates” and/or “Drug Registration Approvals” for an inactivated whole-virus influenza vaccine, an influenza virus split vaccine, a live attenuated varicella vaccine, and a lyophilized nasal spray live attenuated influenza vaccine. He has also served as the principal investigator for numerous provincial-level key science and technology projects, including the first batch of projects under the “Jilin Province Major Special Science and Technology R&D Project Talent Team Support Program.” He has been awarded such honors as “Second-Level Candidate in the Fifth Batch of Top-notch Innovative Talents of Jilin Province,” “Third-Level Candidate in the Fourth Batch of Top-notch Innovative Talents of Jilin Province,” “Fifth Batch of Experts with Outstanding Contributions in Changchun City,” and “First List of Selected Talent Teams for Major Science and Technology Projects in Jilin Province.”
Yan Kunming
Vice President of the Institute of Pharmaceutical Research
Graduated from the former Bethune Medical University (now the Bethune School of Medicine at Jilin University) with a Bachelor of Medicine degree; in 2005, graduated from the Changchun Institute of Biological Products with a Master of Science degree.
Since graduation, I have been engaged in the development and manufacturing of vaccines and biologics for more than 30 years, holding positions at the Changchun Institute of Biological Products, Dalian Yalifeng Biopharmaceutical Co., Ltd. (now Fosun Yalifeng (Dalian) Biopharmaceutical Co., Ltd.), and Changchun Beacon Biotechnology Co., Ltd. My roles have included Director, Head of Production, Production Director, R&D Director, and Deputy Director of the Drug Research Institute, where I was responsible for technical management, project management, regulatory registration, facility operations, and business development. I have participated extensively in GMP certification and compliance inspections, accumulating substantial experience in both R&D and manufacturing. My primary research focus is on the development and industrialization of viral vaccines; I have also been involved in negotiating outsourcing research contracts and facilitating technical communication for recombinant protein vaccines and antibodies against multiple infectious diseases, as well as managing end-to-end project coordination and process development for outsourced recombinant protein vaccines and antibody products. I specialize in the development and commercialization of genetically engineered hepatitis B vaccines, split influenza vaccines, human rabies vaccines, and conjugate vaccines, and have secured numerous clinical trial approvals and manufacturing licenses.
Main Work Experience:
From 2005 to 2014, served at Dalian Yalifeng Biopharmaceutical Co., Ltd. as Production Manager and then Production Director.
From 2014 to 2017, served at the Changchun Institute of Biological Products Co., Ltd. as Deputy Director of the Vaccine Research Laboratory and Vaccine Division I.
From 2017 to January 2023, served at Changchun Bio-Pharmaceutical Co., Ltd., holding the positions of Deputy Director of the Drug Research Institute and Director of R&D.
Since January 2023, has served as the Deputy Director of the Institute of Pharmaceutical Research at Changchun Bio-Pharmaceutical Technology Co., Ltd.
Has participated in and successfully completed several key national science and technology projects, including the “National Science and Technology Support Program—Emergency Research and Development of Novel Drugs and Vaccines for the Prevention and Control of Human and Avian Influenza (Project No. 2006BAI01B03)” and the “National High-Tech Research and Development Program (863 Program)—Research on a Subunit Vaccine for Influenza A (H1N1) (Project No. 2010AA022902).”
Has repeatedly participated in GMP certification inspections, the planning and construction of R&D centers, and the design and construction of GMP-compliant facilities, including influenza vaccine, rabies vaccine, and secondary packaging workshops.
Wu Jinchang
Vice President of the Institute of Pharmaceutical Research
Postdoctoral Researcher, Uppsala University, Sweden
Since 2010, Vice President of the Drug Research Institute at Changchun Bio-Pharmaceutical Technology Co., Ltd.
The company has successfully established a comprehensive and mature manufacturing process that spans from the synthesis and purification of active pharmaceutical ingredients to the formulation of finished dosage forms, and is now capable of producing peptide APIs on a commercial scale. It has also led and participated in numerous domestic and international technology collaboration projects in the biopharmaceutical field, forging partnerships with research institutions in the United States, Switzerland, Russia, Australia, as well as several domestic organizations, thereby accelerating the time-to-market for new drugs. In addition, the company has made significant strides in both innovative drug development and generic drug research, achieving remarkable results. Committed to academic research, it has made outstanding contributions in areas such as the optimization and design of lead compounds and their pharmacological and toxicological evaluation; the synthesis of nucleotides and related compounds along with studies on their anti-tumor and antiviral activities; and chiral analysis and separation in organic synthesis. Furthermore, the company actively promotes and leads international technological cooperation and the introduction of cutting-edge technologies, regularly engaging in technical exchanges with leading pharmaceutical companies abroad to ensure the smooth execution of all international collaborative initiatives and garnering strong support from the World Health Organization (WHO). To date, the company has successfully introduced the RSV project and the Hib project originally funded by Dutch investors, as well as the WHO nasal spray influenza vaccine project.
Key Work Experience and Honors:
Served as the principal collaborator on one National Natural Science Foundation of China project;
Served as the technical lead for one project funded by the National Development and Reform Commission;
Two projects funded by the National Natural Science Foundation of China;
As the project leader, he/she undertook the “12th Five-Year Plan” major special project titled “Construction of the Changchun Biocare Peptide Drug and Innovative Vaccine Incubation Base” (Project No.: 2011ZX09401025), which has since passed acceptance inspection. Under this project, two new drug certificates were applied for, three production approvals (including supplementary production approvals) were submitted, and one supplementary production approval was granted; two clinical trial approvals were applied for, and one clinical trial approval was obtained; eleven invention patent applications were filed, four invention patents were granted, and three invention awards were received; in addition, one Third Prize for Provincial Scientific and Technological Progress and one First Prize for Municipal Scientific and Technological Progress were awarded.
The “Outstanding Foreign Expert” title awarded by the Changchun Municipal People’s Government in 2011;
The “Changchun Friendship Award” conferred by the Changchun Municipal People’s Government in 2012;
The title of “Third-Tier Candidate in the Third Batch of Top-notch Innovative Talents of Jilin Province,” conferred by the People’s Government of Jilin Province in 2012;
In 2013, the Foreign Affairs Office of the Changchun Municipal People’s Government, the Jilin Provincial Department of Human Resources and Social Security, and the Jilin Provincial Department of Education jointly conferred the title of “Outstanding Foreign Expert of Jilin Province.”
Zang Yang
Executive Vice President of the Institute of Pharmaceutical Research
Graduated from the College of Life Sciences at Jilin University with a Ph.D. in Microbiology, and completed postdoctoral research at the University of Alabama at Birmingham (UAB) in the United States.
The organization has successfully completed the research and development of multiple viral vaccines, bacterial vaccines, genetic-engineering vaccines, and monoclonal antibodies. To date, its internally developed projects have secured eight clinical trial approvals, while projects in which it has participated have obtained three manufacturing licenses and two additional clinical trial approvals. The organization has published seven SCI-indexed papers, filed eight invention patent applications, and submitted two PCT patent applications. Currently, the organization serves as the Director of the Jilin Province Baik Vaccine Science and Technology Innovation Center, a member of the Leading Group of the company’s Postdoctoral Research Station, and a member of its Expert Academic Committee. It also holds positions as a member of the Vaccine Testing Technology Branch of the China Vaccine Industry Association, a member of the Basic Research Professional Committee of the China Vaccine Industry Association, and an Executive Committee Member of the Biologics Professional Committee of the Jilin Provincial Pharmaceutical Society.
Key Work Experience and Honors:
During the postdoctoral research period, engaged in the development of bispecific antibodies for cancer.
Since 2015, he has been employed by this company, holding successive positions as Project Director, Manager of the Project Management Department, Deputy Director of R&D, and Director of R&D. He currently serves as Executive Vice President of the Drug Research Institute and Director of R&D, responsible for the overall operation of the R&D system.
Awarded the title of “Key Talent of the New Area.”